Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interaction of platelet factor 4 with human platelets.

A M Capitanio, S Niewiarowski, B Rucinski

    Biochimica Et Biophysica Acta
    |April 17, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Low Affinity Platelet Factor 4 and High Affinity Platelet Factor 4 - Two Antiheparin Factors Secreted by Human Platelets.

    Thrombosis and haemostasis·2019
    Same author

    Development of new antiatherosclerotic and antithrombotic drugs utilizing F11 receptor (F11R/JAM-A) peptides.

    Biopolymers·2014
    Same author

    The immunomodulatory role of angiocidin, a novel angiogenesis inhibitor.

    Current pharmaceutical design·2009
    Same author

    DNAzymes to mouse beta1 integrin mRNA in vivo: targeting the tumor vasculature and retarding cancer growth.

    Cancer gene therapy·2009
    Same author

    Genomic structure, organization and promoter analysis of the human F11R/F11 receptor/junctional adhesion molecule-1/JAM-A.

    Gene·2005
    Same author

    Endothelial apoptotic activity of angiocidin is dependent on its polyubiquitin binding activity.

    British journal of cancer·2005

    Platelets bind platelet factor 4 (PF4) to specific surface sites, influencing aggregation. This binding is enhanced by thrombin and involves PF4’s association with the platelet cytoskeleton, suggesting a role in platelet activation.

    Area of Science:

    • Hematology
    • Biochemistry
    • Cell Biology

    Background:

    • Platelet factor 4 (PF4) is an alpha-granule protein released upon platelet activation.
    • The specific binding sites and functional role of PF4 on the platelet surface are not fully elucidated.

    Purpose of the Study:

    • To investigate the binding characteristics of PF4 to human platelets.
    • To determine the functional consequences of PF4 binding on platelet activity.
    • To explore the interaction of PF4 with the platelet cytoskeleton.

    Main Methods:

    • Radioligand binding assays using 125I-labeled PF4.
    • Scatchard plot analysis to characterize binding sites.
    • Competition assays with unlabeled PF4, heparin, and anti-PF4 Fab fragments.

    Related Experiment Videos

  • Analysis of PF4 association with the Triton X-100-insoluble cytoskeletal fraction.
  • Assessment of platelet aggregation and secretion inhibition assays.

    • Main Results:

    • Resting platelets exhibit saturable binding of PF4, suggesting specific binding sites.
    • PF4 binding is inhibited by unlabeled PF4, heparin, and anti-PF4 Fab fragments.
    • Bound PF4 associates with the platelet cytoskeleton upon thrombin stimulation, an interaction inhibited by anti-PF4 Fab fragments and heparin.
    • Anti-PF4 Fab fragments inhibit thrombin-induced platelet aggregation and secretion, while anti-beta-thromboglobulin antibodies do not.
    • No significant binding of beta-thromboglobulin or its antibodies to platelets was observed.

    Conclusions:

    • PF4 binds to specific sites on the platelet surface.
    • PF4 binding and subsequent cytoskeletal association play a role in modulating platelet aggregation and secretion.
    • These findings highlight PF4's function beyond its role as an alpha-granule component, impacting platelet responsiveness.